L-J Xu
Overview
Explore the profile of L-J Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Yang Y, Xu L, Deng Y, Fu J
J Physiol Pharmacol
. 2023 Sep;
74(3).
PMID: 37661184
To explore the molecular mechanisms related to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) resistance, along with potential therapeutic targets and strategies. The autophagy and Beclin 1 regulator 1 (Ambra1)...
2.
Chen T, Li J, Zhou M, Xu L, Pan T
Eur Rev Med Pharmacol Sci
. 2020 Apr;
24(7):3734-3740.
PMID: 32329850
Objective: To illustrate the role of interleukin 6 (IL-6) in the progression of non-small cell lung cancer (NSCLC) via activating STAT1. Patients And Methods: The level of IL-6 mRNA in...
3.
Zheng Z, Ma Y, Wu R, Rong G, Li C, Li G, et al.
Eur Rev Med Pharmacol Sci
. 2020 Feb;
24(2):777-783.
PMID: 32016982
Objective: MiRNA-133 (miR-133) has been identified as a tumor suppressor in many types of human cancers. However, its clinical significance in acute myeloid leukemia (AML) is still unclear. The purpose...
4.
Yao R, Feng W, Xu L, Zhong X, Liu H, Sun Y, et al.
Eur Rev Med Pharmacol Sci
. 2018 Aug;
22(15):4934-4940.
PMID: 30070329
Objective: To investigate the role of DUXAP10 in chronic myelogenous leukemia (CML) and its underlying mechanism. Patients And Methods: We detected DUXAP10 expression in 82 CML patients, 12 normal controls,...
5.
Feng W, Yao R, Xu L, Zhong X, Liu H, Sun Y, et al.
Eur Rev Med Pharmacol Sci
. 2018 Jul;
22(14):4564-4572.
PMID: 30058689
Objective: To investigate the potential effect of miR-363 on the development of laryngeal cancer and to reveal the relevant mechanism. Patients And Methods: The expression level of miR-363 was detected...
6.
Xu L, Yu X, Wei B, Hui H, Sun Y, Dai J, et al.
Eur Rev Med Pharmacol Sci
. 2018 May;
22(9):2646-2652.
PMID: 29771416
Objective: The purpose of this research was to detect the expression of long non-coding RNA DUXAP8 in esophageal cancer, and to explore its underlying mechanism in the development of esophageal...
7.
Xu L, Yu X, Wei B, Hui H, Sun Y, Dai J, et al.
Eur Rev Med Pharmacol Sci
. 2018 May;
22(9):2653-2661.
PMID: 29771415
Objective: Our research studied the expression of long noncoding RNA (lncRNA) SNHG7 in esophageal cancer cells and tissues. The effect of lncRNA SNHG7 on proliferation and apoptosis of esophageal cancer...
8.
Dai J, Xu L, Han G, Sun H, Zhu G, Jiang H, et al.
Eur Rev Med Pharmacol Sci
. 2018 Apr;
22(7):1884-1890.
PMID: 29687839
Objective: To explore the role of microRNA (miR) 137 in spinal cord injury and its mechanism. Materials And Methods: The model of spinal cord injury in mice was established to...
9.
Dai J, Xu L, Han G, Sun H, Zhu G, Jiang H, et al.
Eur Rev Med Pharmacol Sci
. 2018 Feb;
22(3):582-589.
PMID: 29461585
Objective: Spinal cord injury (SCI) is a severe trauma to the central nervous system. Long non-coding RNAs have been reported to play essential roles in spinal cord injury. This study...
10.
Liu M, Xu L, Wu J
Genet Mol Res
. 2015 Dec;
14(4):15930-6.
PMID: 26662384
The aim of this study was to investigate the changes of circulating CD4(+)CD25(+)CD127(low) regulatory T cells (Treg) in patients with acute coronary syndrome (ACS) and its significance. The experiment was...